Ilixadencel - Immunicum

Drug Profile

Ilixadencel - Immunicum

Alternative Names: Allogeneic cancer vaccine - Immunicum; COMBIG-DC; Dendritic cell vaccine - Immunicum; INTUVAX-GIST; INTUVAX-HCC; INTUVAX-RCC

Latest Information Update: 24 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Immunicum
  • Developer Immunicum; Uppsala University
  • Class Cancer vaccines; Dendritic cell vaccines
  • Mechanism of Action Cytotoxic T lymphocyte stimulants; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Renal cell carcinoma
  • Phase I/II Gastrointestinal stromal tumours
  • No development reported Liver cancer

Most Recent Events

  • 23 Jul 2018 US FDA approves the clinical trial protocol for phase Ib/II ILIAD trial in Cancer (combination therapy, Late-stage disease)
  • 22 May 2018 Immunicum completes enrolment in its phase I/II trial for Gastrointestinal stromal tumours (Late-stage disease, Metastatic disease, Second-line therapy or greater) (GIST) in Sweden
  • 21 May 2018 Phase-I/II clinical trials in Gastrointestinal stromal tumours (Late-stage disease, Metastatic disease, Second-line therapy or greater) in Sweden (Intratumoural)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top